[144] Catalyst Pharmaceutical Inc. SEC Filing

Rhea-AI Filing Summary

Catalyst Pharmaceuticals (CPRX) filing a Form 144 notifies the proposed sale of 22,970 common shares by a person for whose account the securities are to be sold, with an aggregate market value of $473,641.40. The shares are held at Fidelity Brokerage Services and the approximate sale date is 08/26/2025 on NASDAQ. The filing shows the shares were acquired on 08/26/2025 pursuant to an option granted on 12/19/2018, and the planned consideration is cash. The filer also reported a prior sale of 70,000 shares on 05/30/2025 generating gross proceeds of $1,740,171.80. The filer attests no undisclosed material adverse information.

Positive

• Disclosure compliance: The filer provides required Rule 144 details including broker, number of shares, acquisition date, and nature of acquisition.
• Prior sale disclosed: The filing reports the 05/30/2025 sale of 70,000 shares with $1,740,171.80 gross proceeds, improving transparency about recent insider transactions.

Negative

• Insider selling activity: A proposed sale of 22,970 shares and a recent sale of 70,000 shares represent substantial insider liquidity events that investors may view as noteworthy.

Insights

Securities Analyst

TL;DR: Insider intends to sell ~22.97k shares (≈$474k) and previously sold 70k shares (~$1.74M), indicating notable insider liquidity activity.

The Form 144 shows a planned sale of 22,970 common shares through Fidelity on NASDAQ with an aggregate market value of $473,641.40, acquired via an option originally granted 12/19/2018. The filer also reported a 70,000-share sale on 05/30/2025 that produced $1,740,171.80 in gross proceeds. For investors, these are factual disclosures of insider selling activity and do not include any commentary on intent or company fundamentals.

Corporate Governance Expert

TL;DR: Document is a routine Rule 144 notice documenting planned insider sale; it includes acquisition details and prior recent sales.

The filing complies with Rule 144 disclosure requirements by listing the class, broker, quantity, acquisition date and nature (option grant), and planned sale date. It also discloses a significant recent sale (70,000 shares). The signer affirms no undisclosed material adverse information. The filing itself is procedural and does not disclose governance changes or other corporate actions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	22970	473641.40	122391010	08/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/26/2025	Option Granted - 12/19/2018	Issuer			22970	08/26/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Richard Daly 355 Alhambra Circle Suite 801 Coral Gables FL 33134	Common	05/30/2025	70000	1740171.80

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for CPRX disclose?

It discloses a proposed sale of 22,970 common shares (aggregate value $473,641.40) planned for 08/26/2025 via Fidelity on NASDAQ, and a prior sale of 70,000 shares on 05/30/2025 for $1,740,171.80.

How were the 22,970 CPRX shares acquired?

The shares were acquired under an option granted on 12/19/2018 and are to be sold for cash.

Who is the broker handling the proposed CPRX sale?

Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI) is named as the broker of record.

When did the filer previously sell CPRX shares and for how much?

The filer sold 70,000 shares on 05/30/2025, generating gross proceeds of $1,740,171.80.

Does the filer claim any undisclosed material information about CPRX?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.